Todd Davis: Expending Portfolio and Setting ambitious growth targets

Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn:

“On the Ligand Pharmaceuticals earnings call this week, I highlighted the steps we have taken to transform the company over the past 18 months and strengthen and expand our royalty portfolio and team. I am pleased to report that during the first half of 2024, we committed $175 million to two new investment opportunities. One of these transactions was the acquisition of APEIRON Biologics, a $100 million investment, and one of our most recent commitments of capital across our platform.

We also added four commercial-stage products to our portfolio and expanded the bench strength of our investment, business development, and operational teams with several new hires.

I am proud of our tremendous progress during the first half of 2024. We have set ambitious yet realistic targets for long-term growth and believe we are well-positioned to create further value for our shareholders.”

Source: Todd Davis/LinkedIn